Pharmacological Evaluation of Anti-Diabetic Activity of Myricetin in Different Cell Lines

Abstract

The aim of this research work was to perform pharmacological evaluation of Myricetin by using different cell lines. To check the short-term cytotoxic effect of Myricetin in HepG2 and L6 cells, a colorimetric based MTT assay was performed also the glucose utilization in both HepG2 and L6 cells was estimated in order to measure the in vitro anti-diabetic activity of Myricetin. For Lipid accumulation T3-L1 preadipocytes cells are used. For measurement of nitric oxide (NO) the RAW-264.7 cells are used. The alpha-amylase assay and alpha-glucosidase inhibition assay was performed to check if our drug is having effect in term of inhibiting α-amylase and α-glucosidase respectively. Western blot analysis was performed to check the expressions of iNOS protein in LPS treated RAW 264.7 cells before and after the exposure of Myricetin. The cytotoxicity data suggested that Myricetin displayed low level of cytotoxicity in HepG2 cells and in L6 myoblast cell lines. For glucose utilization experiment, it discovered that glucose uptake level was notably increase in HepG2 cells and in L6 myoblast cell lines with the increasing concentration of Myricetin. Myricetin increase lipid accumulation in 3T3-L1 preadipocytes and also inhibits nitric oxide production in RAW 264.7 cell lines. Research was found that Myricetin had no significant effect in order to alter the expression of alpha-amylase and alpha-glucosidase. Our research concludes that Myricetin can be used as a potent anti-diabetic agent.